Oramed Pharmaceuticals to Present at the American Diabetes Association 74th Scientific Sessions on June 13 - 17, 2014 in San Francisco

Jun 10, 2014, 08:15 ET from Oramed Pharmaceuticals

JERUSALEM, June 10, 2014 /PRNewswire/ --


Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that three scientific abstracts summarizing studies performed with ORMD-0801, its orally ingestible insulin capsule, were accepted for inclusion at the American Diabetes Association 74th Scientific Sessions, which will take place in San Francisco.

Two abstracts will be presented at poster sessions and all three will be published in the Scientific Sessions Abstract Book. The posters will be attended by Oramed's Chief Scientific Officer, Dr. Miriam Kidron.

Abstract Information 

1. Title: Comparative Assessment of the Glucose-Lowering Effect of Multiple Oral Insulin (ORMD-0801) Formulation Variants in Pigs (for publication only)

2. Title: Bedtime Oral Insulin Lowers Fasting Blood Glucose Levels in T2DM Patients

Poster Session: Sunday, June 15th, 2014, 12pm-2pm Pacific time, Hall D

3. Title: Improved Oral Insulin Bioavailability when Delivered in Soft Capsules 

Poster Session: Sunday, June 15th, 2014, 12pm-2pm Pacific time, Hall D

About the American Diabetes Association (ADA) Scientific Sessions 

The ADA's Scientific Sessions brings together scientists and health care professionals

from around the world who are involved in diabetes research and care. The five-day

meeting features the most timely and significant advances in the prevention, diagnosis,

and treatment of diabetes. The program includes presentations by world-renowned diabetes experts.

For more information on the ADA, please refer to their website: http://www.diabetes.org. More information on the Scientific Sessions can be found at http://professional.diabetes.org/Congress_Display.aspx?TYP=9&CID=93229

About ORMD-0801 Oral Insulin 

Oramed's ORMD-0801 is an orally ingestible insulin capsule for the early stages of type 2 diabetes, when it can still slow the rate of degeneration of the disease by providing additional insulin to the body and allowing pancreatic respite. Moreover, orally administered insulin has the potential benefit of enhanced patient compliance at this crucial stage as well as the advantage of mimicking insulin's natural location and gradients in the body by first passing through the liver before entering the bloodstream. For more information on ORMD-0801, the content of which is not part of this press release, please visit: http://oramed.com/index.php?page=14,

About Oramed Pharmaceuticals 

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in separate Phase II clinical trials in patients with both type 1 and type 2 diabetes under an Investigational New Drug (IND) application with the U.S. FDA, and with its oral GLP-1 analog capsule (ORMD-0901) entering IND-enabling studies later this year.

For more information, the content of which is not part of this press release, please visithttp://www.oramed.com

Forward-looking statements:  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials, including the expected design or timing thereof, the effects of ORMD-0801 and oral insulin in general, and revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals        
Aviva Guiloff                
Office: +972-2-566-0001 ext. 2
US: +1-718-831-2512 ext. 2
Email: aviva@oramed.com 

US Investor Relations Contact:
LifeSci Advisors LLC
Andrew McDonald
US: +1-646-597-6987
Email: andrew@lifesciadvisors.com

SOURCE Oramed Pharmaceuticals